BPC-157 + TB-500 + Cartalax
Also known as: BPC-157 / TB-500 / Cartalax blend, Tissue Repair Triple Blend
Pre-mixed three-peptide blend marketed for tissue repair and recovery, combining BPC-157 (a synthetic gastric-pentapeptide fragment), TB-500 (a synthetic Thymosin β4 fragment that promotes actin regulation and cell migration), and Cartalax (a synthetic Lys-Glu-Asp tripeptide, AED-related, marketed for cartilage and connective-tissue support). Each component is an individually grey-market research compound with no FDA-approved human indication; the blend itself has no published controlled human efficacy or safety data. Any rationale is inferred from preclinical and uncontrolled reports on the separate peptides, and combination-specific human data is lacking.
Who's worth your money for BPC-157 + TB-500 + Cartalax
Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.
Top Merit pick
Highest Merit Score (60) of 1 scored sellers
$120 · 20mg
Average price
$6.00/mg
Sellers
2
45-day trend
0%
1 of 2 sellers have a current price
- 🇺🇸 Certified Peptides60
✓ verified at source · 9h ago
$6.00/mg 0% vs avg$120
20mg
no purity
Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.
Watch BPC-157 + TB-500 + Cartalax
Get one email when the market actually moves — no newsletter, no noise.
About BPC-157 + TB-500 + Cartalax
CAS
—
Molecular formula
—
Typical dose range
No validated blend protocol exists. Vendor norms for the components: BPC-157 250–500 mcg/day subcutaneous; TB-500 2–5 mg/week subcutaneous; Cartalax 1–2 mg/day subcutaneous or intranasal. Research use only.
Half-life
Component-dependent and not characterized for the mixture. BPC-157: disputed (minutes to ~4 hours, subcutaneous); TB-500: ~2 hours plasma; Cartalax: short peptide half-life, not well characterized in humans.
Common research uses
Safety notes
Not FDA-approved in any form; sold as a research/grey-market compound. No combination-specific human safety data; the long-term and interaction safety profile of the three peptides together is unknown. Purity and content of grey-market blends are unverified absent a third-party COA.
Reconstitution
Supplied lyophilized; reconstitute with bacteriostatic water and refrigerate. As an unapproved multi-peptide research preparation, sterility, dose accuracy and stability of the mixed components are not assured.
COAs for BPC-157 + TB-500 + Cartalax
2 third-party tests across 2 vendors. Each card links to the full report.
Research use only. Not for human consumption and not approved by the FDA. Nothing here is medical advice.